Web Exclusives
Web Exclusives — March 23, 2021
A greater number of comorbidities alone may not be sufficient to predict patient survival; age and stage at diagnosis must be considered as well. Read More ›
Web Exclusives — March 23, 2021
The first phase 3 trial comparing these drugs shows that acalabrutinib has similar efficacy as ibrutinib with a lower risk of a worrisome side effect. Read More ›
By Rosie Kelly
Web Exclusives — March 16, 2021
Social workers serve as “dot connectors” to help patients with cancer overcome barriers. Today, on World Social Work Day, CONQUER magazine celebrates social workers everywhere. Read More ›
Web Exclusives — March 12, 2021
As we reflect on 1 year of living in a pandemic, here’s what we’ve learned about COVID-19, cancer, and the road ahead. Read More ›
Web Exclusives — March 1, 2021
Arming yourself with a healthy diet during and after cancer treatment can optimize healing and improve your quality of life. Read More ›
Web Exclusives — February 23, 2021
Although the use of telemedicine has been increasing due to the COVID-19 pandemic, it has not completely replaced the need for in-person visits. Read More ›
Web Exclusives — February 23, 2021
A federal law protects consumers from receiving bills covering the balance of many out-of-network emergency medical services. Read More ›
Web Exclusives — February 23, 2021
Combined acalabrutinib, venetoclax, and obinutuzumab have shown favorable efficacy and tolerability in untreated patients in an ongoing phase 2 study. Read More ›
Web Exclusives — February 23, 2021
The need to protect patients and healthcare workers from contracting COVID-19 has resulted in many changes to how hospital care is delivered. Read More ›
Web Exclusives — February 23, 2021
Recent data suggest that patients with CLL who received treatment with a BTK inhibitor had a rate of developing a second cancer over twice as high as that expected in the general population. Read More ›